Literature DB >> 23721853

Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy.

Deb Feldman-Stewart1, Yolanda Madarnas, Mihaela Mates, Christine Tong, Eva Grunfeld, Shailendra Verma, Hannah Carolan, Michael Brundage.   

Abstract

PURPOSE: To identify the information that post-menopausal women with hormone-receptor positive, early-stage breast cancer want, to help them decide among six treatment options for adjuvant-endocrine therapy.
METHODS: We surveyed women with early-stage breast cancer who were eligible for adjuvant endocrine-therapy 3-18 months earlier. Participants rated the importance of getting each of 95 questions answered before this decision is made (options: essential/desired/not important/avoid). For questions rated essential or desired, participants identified the purpose(s) for having the question answered: to help them understand, make the decision, plan, or other. Participants indicated the role they played in their actual decision and the role they would prefer if the decision was made today. They also indicated whether they felt they had had a choice of endocrine therapy treatments.
RESULTS: 188 of 343 questionnaires were returned (response rate 55%). Mean age was 67 yr (range 38-88 yr); 76% were married, and 39% had secondary school education or less. On average, respondents rated 18 questions (range 0-94) essential for decision making. Each question was rated essential for decision making by ≥ 7% of participants but only 1 question by >50%. Regarding roles, 89% of respondents had participated in their actual decision and would want to again; an additional 9% had not participated in their actual decision but would want to at the time of the survey. The percentage of respondents who felt they had no choice of endocrine therapy treatments varied between centres, 25% vs 41% and 49%.
CONCLUSIONS: Most patients want to participate in the decision but they vary widely in the amount and which specific details they want to help them make the decision. IMPLICATION: The wide variation in questions considered important means the support should be tailored to the needs of the individual patient.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant endocrine therapy decision; Breast cancer; Patient decision making

Mesh:

Substances:

Year:  2013        PMID: 23721853     DOI: 10.1016/j.breast.2013.04.020

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.

Authors:  G J van Londen; Heidi S Donovan; Ellen B Beckjord; Alexandra L Cardy; Dana H Bovbjerg; Nancy E Davidson; Jennifer Q Morse; Galen E Switzer; Irma M Verdonck-de Leeuw; Mary Amanda Dew
Journal:  Oncol Nurs Forum       Date:  2014-11-01       Impact factor: 2.172

2.  Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors.

Authors:  N J Lipton; J Jesin; E Warner; X Cao; A Kiss; D Desautels; K J Jerzak
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

3.  Lessons learned from a cancer knowledge translation grants program: results of an evaluation.

Authors:  M A O'Brien; T Makuwaza; I D Graham; L Barbera; C C Earle; M C Brouwers; E Grunfeld
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.